564 related articles for article (PubMed ID: 28475932)
21. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
23. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
[TBL] [Abstract][Full Text] [Related]
24. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
Gülben K; Berberoğlu U; Kinaş V; Başkan E
Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
[TBL] [Abstract][Full Text] [Related]
27. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
[TBL] [Abstract][Full Text] [Related]
28. Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy.
Cohen BL; Collier AL; Kelly KN; Goel N; Kesmodel SB; Yakoub D; Moller M; Avisar E; Franceschi D; Macedo FI
Ann Surg Oncol; 2020 Jun; 27(6):1830-1841. PubMed ID: 31989360
[TBL] [Abstract][Full Text] [Related]
29. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
Park S; Lee SK; Paik HJ; Ryu JM; Kim I; Bae SY; Yu J; Kim SW; Lee JE; Nam SJ
Medicine (Baltimore); 2017 Jun; 96(22):e6777. PubMed ID: 28562530
[TBL] [Abstract][Full Text] [Related]
31. [Clinical characteristics and prognosis of different subtypes of breast cancer].
Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
[TBL] [Abstract][Full Text] [Related]
32. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
[TBL] [Abstract][Full Text] [Related]
33. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Coates AS; Winer EP; Goldhirsch A; Gelber RD; Gnant M; Piccart-Gebhart M; Thürlimann B; Senn HJ;
Ann Oncol; 2015 Aug; 26(8):1533-46. PubMed ID: 25939896
[TBL] [Abstract][Full Text] [Related]
34. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
35. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA
Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.
Stauder MC; Caudle AS; Allen PK; Shaitelman SF; Smith BD; Hoffman KE; Buchholz TA; Chavez-Macgregor M; Hunt KK; Meric-Bernstam F; Woodward WA
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):637-44. PubMed ID: 27681760
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
38. Effect of axillary lymph node dissection after sentinel lymph node biopsy on overall survival in patients with T1 or T2 node-positive breast cancer: report from the Korean Breast Cancer Society.
Park HS; Chae BJ; Song BJ; Jung SS; Han W; Nam SJ; Youn HJ; Ko BK; Kim DW;
Ann Surg Oncol; 2014 Apr; 21(4):1231-6. PubMed ID: 24318094
[TBL] [Abstract][Full Text] [Related]
39. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy?
Sanuki N; Takeda A; Amemiya A; Ofuchi T; Ono M; Ogata H; Yamagami R; Hatayama J; Eriguchi T; Kunieda E
Clin Breast Cancer; 2013 Feb; 13(1):69-76. PubMed ID: 23062706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]